*Ocata Daily Discussion* 1.0

Hi JHam,

FYI, link redirected me to home page...assume you intended to reference new rule enforcement thread instead.

Cheers

I will start this fresh thread with a few questions that have been on my mind for a while.  I would love to hear some of your opinions, especially tradeup or anyone else participating in the offering.

If, or when, the final prospectus does come out with a discount and or warrants, what are your thoughts on what the PPS will do?  

I am a little in the dark as to the possibilities.  If the offering is announced at 5.50 does the PPS all of a sudden gap down to 5.50? or more?  I have seen mention of a possible oversubscription which to my understanding means there is more demand for the 10 million. If this happens do the buyers purchase on the open market?  Does the PPS react accordingly without the knowledge of those involved in the offering, mainly us?  How long does the offering usually take and what do you see the PPS doing in the mean time?

I know it is a load of questions but I know many here have their theories as to what the PPS will do when the offering is announced.  Thanks in advance 
 

some must be in the know how our subscription is going?does our rise in the pps reflect that knowledge and will it until the closing?i think so!big chunks are selling today at higher prices which seems to support this assumption.my only question is:who is selling?the closing price getting pushed down every day makes me think that lincoln is still getting shares.if i remember correctly the average over 10 days or 3 days closing determines the # for lincoln buys.

I read one about butterflies.

I still think there will be a discount, but if the pps can continue to rise like it has the past few days it would make that discount a lot easier to swallow for current shareholders.

I think you should have waited and sold it prior to the ipo date. This thing is sure to go up until then. Can't say what happens after that :-)

We shouldn't confuse this with an IPO, it's a secondary offering + uplist ("re-IPO") with 10-11.5M shares being added to the outstanding -- likely 11.5M.

The price of $7 x 45.9M shares (34.4 + 11.5M) equals a Market Cap of approx $317M. We are many months away from P2 AMD initiation and 1.5-2.5 years away from meaningful data.

I don't expect equity participants (myself included) to be buying at such a premium.

TMF,
I believe both the presentation on the website and the roadshow indicate both SMD and AMD data in mid 2016 which would be 1.5 years away. I think he was padding it since history has shown there can be delays. I think Eddy is probably much better with putting up a realistic timeline but delays happen for all sorts of reasons, many of which are uncontrollable, so I wouldn't be shocked if there is one. I don't think they have been indicating that SMD patient data would be available before AMD data though. 

Could be.  But it is interesting that OCAT is going after later stage patients with GA as their primary target market, not earlier stage patients as many here (including me) originally thought based on prior company statements.  Not sure why that change in direction, as all commentary prior to the release of the Phase 2 endpoints was that earlier stage patients was the target.